Anna Eshoo: “So will you work with us to strengthen that?”

I see, as I expressed to you when we spoke, a disconnect between CMS, the FDA, and the VA on new treatments for mild Alzheimer's.

The PBM Accountability Act will finally shed a light on the opaque drug pricing system.

I find it hypocritical when I hear time and time and time again that plans are often blocked by PBMs from offering the lowest-priced generic.

I have to say that I am really deeply disappointed. Deeply disappointed.